Novartis AG: Balancing Promising Drug Developments with Market Challenges – Hold Recommendation

Analyst James Quigley from Goldman Sachs maintained a Hold rating on Novartis AG and decreased the price target to CHF95.00 from CHF97.00.

James Quigley has given his Hold rating due to a combination of factors related to Novartis AG’s recent developments and market conditions. The company announced promising topline data for ianalumab in trials for Sjogren’s syndrome, a condition with no approved treatments, suggesting potential for significant market impact. However, while the drug shows potential with projected peak sales, the market seems to assign a lower probability of success, which could temper immediate share price reactions until more detailed data is available.
Additionally, Quigley notes that Novartis faces challenges such as upcoming generic competition impacting $32 billion in sales by 2030 and a period of limited news flow until 2026. These factors contribute to a cautious outlook, balancing the positive pipeline developments with the broader market and competitive landscape challenges, leading to the Hold recommendation.

In another report released on August 8, Morgan Stanley also upgraded the stock to a Hold with a CHF100.00 price target.

NOVN’s price has also changed slightly for the past six months – from CHF98.040 to CHF96.020, which is a -2.06% drop .